Formulation and Evaluation of Colon Targeted Tablets of Mesalazine
Abstract
In the present investigation an attempt was made to formulate the time and pH dependent drug delivery system, reduce the frequency of dose administeration, to prevent ulcerative colitis by developing sustained delayed release tablets of Mesalazine using combination of Eudragit S-100 and L-100 as enteric coating. The core tablets of Mesalazine were prepared using wet granulation containing a superdisintegrant. The aim of present study is to develop colon specific drug delivery of Mesalazine sustained release matrix tablets for ulcerative colitis using HPMC K-4M and HPMC K-15M as a semisynthetic polymer. Effect of polymer concentration and superdisintegrant level was also investigated. The matrix tablets of Mesalazine are subjected to an in-vitro drug release study using simulated gastric fluid (0.1N HCl) for 2 hours, simulated intestinal fluid (pH 7.4) for 3 hours and simulated colonic fluid (pH 6.8) for 7 hours as dissolution fluid. The study showed that, lag time prior to drug release was highly affected by the coating. Colon drug delivery is advantageous in treatment of colonic disease and oral delivery of drugs that are unstable and susceptible to enzymatic degradation in upper GI tract. The disintegration data obtained from tablets demonstrated that disintegration data rate of studied tablets is dependent on: (i) The polymer used to coat the tablets (ii) pH of disintegration media. Results also demonstrated that combination of Eudragit S-100 and L-100 can be successfully used to coat tablets for colon targeted delivery of drug.DOI
https://doi.org/10.22270/jddt.v2i5.290Published
2012-09-15
Statistics
Abstract Display: 1481
PDF Downloads: 1594 How to Cite
1.
Sharma M, Joshi B, Bansal M, Goswami M. Formulation and Evaluation of Colon Targeted Tablets of Mesalazine. J. Drug Delivery Ther. [Internet]. 2012 Sep. 15 [cited 2026 Jan. 23];2(5). Available from: https://www.jddtonline.info/index.php/jddt/article/view/290
Issue
Section
Research
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
1.
Sharma M, Joshi B, Bansal M, Goswami M. Formulation and Evaluation of Colon Targeted Tablets of Mesalazine. J. Drug Delivery Ther. [Internet]. 2012 Sep. 15 [cited 2026 Jan. 23];2(5). Available from: https://www.jddtonline.info/index.php/jddt/article/view/290

.